where-will-moderna-be-in-1-year?

Where Will Moderna Be in 1 Year?

All eyes are on drug manufacturers in 2020 as they race to develop the first coronavirus vaccine. Globally, recorded cases of COVID-19 have surpassed 25 million, with at least 847,000 related deaths worldwide. More than 6 million cases have been reported in the U.S. alone, with at least 183,000 deaths as of Aug. 30.

(NASDAQ: MRNA) reported positive results from the phase 1 trial for its COVID-19 mRNA vaccine in July, and started the phase 3 trial on July 27. It’s no surprise that its stock is up 245% year to date, while the S&P 500 has risen just 9%.” data-reactid=”13″ type=”text”>According to the World Health Organization, there are more than 150 novel coronavirus vaccine candidates in development now, with nearly 30 of them in clinical testing. U.S.-based Moderna (NASDAQ: MRNA) reported positive results from the phase 1 trial for its COVID-19 mRNA vaccine in July, and started the phase 3 trial on July 27. It’s no surprise that its stock is up 245% year to date, while the S&P 500 has risen just 9%.

MRNA Chart

MRNA data by YCharts” data-reactid=”32″ type=”text”>MRNA data by YCharts

Moderna’s vaccine candidate, mRNA-1273, got a boost in April after it received $483 million in funding from the Biomedical Advanced Research and Development Authority. The urgency of ending the pandemic has led governments to expedite the vaccine development process, which usually takes many years. Moderna recently received an additional $472 million through Operation Warp Speed (OWS, a Trump administration initiative) to support its late-stage trials. ” data-reactid=”34″ type=”text”>Moderna’s vaccine candidate, mRNA-1273, got a boost in April after it received $483 million in funding from the Biomedical Advanced Research and Development Authority. The urgency of ending the pandemic has led governments to expedite the vaccine development process, which usually takes many years. Moderna recently received an additional $472 million through Operation Warp Speed (OWS, a Trump administration initiative) to support its late-stage trials.

Lonza Group as its production partner. On Aug. 28, management announced that Moderna is in talks to sell 40 million or more doses of its potential vaccine to Japan’s Ministry of Health, Labour and Welfare, starting in the first half of 2021. It says it is also in “advanced discussions” with the European Commission to supply Europe with 80 million doses. ” data-reactid=”36″ type=”text”>Moderna is scaling up to produce 500 million to 1 billion doses a year beginning in 2021, with Lonza Group as its production partner. On Aug. 28, management announced that Moderna is in talks to sell 40 million or more doses of its potential vaccine to Japan’s Ministry of Health, Labour and Welfare, starting in the first half of 2021. It says it is also in “advanced discussions” with the European Commission to supply Europe with 80 million doses.

under OWS.” data-reactid=”37″ type=”text”>Before this, the U.S. government had already pledged more than $1.5 billion for 100 million doses of Moderna’s potential vaccine, with the option to buy up to an additional 400 million doses under OWS.

View photos

A gloved hand holds up a glass vial labeled “Coronavirus”

Image source: Getty Images.

Moderna’s outlook a year from now is highly dependent on how its vaccine candidate fares in late-stage testing.” data-reactid=”64″ type=”text”>Moderna’s outlook a year from now is highly dependent on how its vaccine candidate fares in late-stage testing.

If its vaccine candidate is successful, it could garner huge revenue for Moderna. However, once the pandemic ends, and if the coronavirus does not return, demand for the vaccine could ultimately decline. Transportation and storage of the potential vaccine, which needs to be kept very cold, could also prove unfavorable for the company if competitors make a vaccine that is easier to transport and store.” data-reactid=”66″ type=”text”>If its vaccine candidate is successful, it could garner huge revenue for Moderna. However, once the pandemic ends, and if the coronavirus does not return, demand for the vaccine could ultimately decline. Transportation and storage of the potential vaccine, which needs to be kept very cold, could also prove unfavorable for the company if competitors make a vaccine that is easier to transport and store.

vaccine development process, many things can go wrong. Vaccines can fail late-stage trials and encounter issues with regulatory approval, and it’s always possible that another drugmaker will come out with a successful vaccine first. ” data-reactid=”67″ type=”text”>Keep in mind that in the vaccine development process, many things can go wrong. Vaccines can fail late-stage trials and encounter issues with regulatory approval, and it’s always possible that another drugmaker will come out with a successful vaccine first. 

For now, Moderna is still unprofitable, but its cash position remains robust. As of June 30, it had $3.1 billion in cash, cash equivalents, and investments. ” data-reactid=”69″ type=”text”>For now, Moderna is still unprofitable, but its cash position remains robust. As of June 30, it had $3.1 billion in cash, cash equivalents, and investments. 

Moderna has tough competition in this race — SinopharmSinovac Biotech, Pfizer, AstraZeneca, and BioNTech have some of the more advanced candidates — but its already soaring shares could skyrocket if its vaccine is approved. Shares of Moderna have gained 245% so far this year, while AstraZeneca and BioNTech are up 12% and 89% and Pfizer has declined by 3.2%. ” data-reactid=”71″ type=”text”>Moderna has tough competition in this race — SinopharmSinovac Biotech, Pfizer, AstraZeneca, and BioNTech have some of the more advanced candidates — but its already soaring shares could skyrocket if its vaccine is approved. Shares of Moderna have gained 245% so far this year, while AstraZeneca and BioNTech are up 12% and 89% and Pfizer has declined by 3.2%.

AZN Chart

AZN data by YCharts” data-reactid=”85″ type=”text”>AZN data by YCharts

biotech stock for aggressive investors who believe better rewards come with greater risk.” data-reactid=”87″ type=”text”>Even if another company surpasses Moderna in the vaccine race, the company can still profit from the other drugs in its pipeline — but it could be years before they bring in revenue. That makes Moderna a good biotech stock for aggressive investors who believe better rewards come with greater risk.

  • 10 Best Stocks to Buy Today
  • The $16,728 Social Security Bonus You Cannot Afford to Miss
  • 20 of the Top Stocks to Buy (Including the Two Every Investor Should Own)
  • What Is an ETF?
  • 5 Recession-Proof Stocks
  • How to Beat the Market
  • Sushree Mohanty has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.” data-reactid=”96″ type=”text”>Sushree Mohanty has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

    Where Will Moderna Be in 1 Year? was originally published by The Motley Fool” data-reactid=”97″ type=”text”>Where Will Moderna Be in 1 Year? was originally published by The Motley Fool

    Leave a Comment

    Your email address will not be published. Required fields are marked *

    Scroll to Top